Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06128863
Title Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial (EFTISARC-NEO)
Acronym EFTISARC-NEO
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Maria Sklodowska-Curie National Research Institute of Oncology
Indications
Therapies
Age Groups: senior | adult
Covered Countries POL


No variant requirements are available.